GlassScriptPhysician profile
Luis D Flores
NPI 1285608216
$24,904.52
in general payments reported to CMS, 2019-2025
50 companies · $3,738 in 2025
The $3,738 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,170 · 2020: $2,754 · 2021: $3,570 · 2022: $3,686 · 2023: $3,622 · 2024: $4,365 · 2025: $3,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $722 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,618.26 |
| Travel and Lodging | $722.03 |
| Education | $384.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,226.07 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $3,214.72 | 2019-2025 | Opdivo, Reblozyl, Breyanzi |
| Astrazeneca Pharmaceuticals LP | $2,680.32 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $2,678.73 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Abbvie INC. | $2,119.39 | 2019-2025 | |
| Pbg Puerto Rico LLC | $1,320.22 | 2019-2025 | |
| Genentech USA, INC. | $1,189.46 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Amgen INC. | $1,149.17 | 2019-2025 | Xgeva, Lumakras, Kyprolis |
| Eli Lilly Export S.A. Puerto Rico Branch | $767.46 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $656.81 | 2019-2025 | Erleada |
| Glaxosmithkline, LLC. | $527.73 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $508.09 | 2021-2025 | |
| Genzyme Corporation | $404.37 | 2019-2025 | |
| Eisai INC. | $387.41 | 2019-2025 | |
| Incyte Corporation | $328.46 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.